{"filings":[{"id":945756,"accession_number":"0001493152-26-027936","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2026-06-09T20:15:25+00:00","items":["5.07"],"status":"ready","headline":"Sanara MedTech annual meeting results: all proposals approved; board adopts triennial advisory vote on exec comp","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected, with each receiving >5M for votes (including Yon, Nixon, DeSutter).","Weaver and Tidwell ratified as auditor for FY2026: 6,696,035 for, 2,198 against.","Advisory say-on-pay approved: 5,280,546 for (98.9% of votes cast).","Frequency vote favors three years (4,296,133); board sets triennial advisory vote on exec comp, next vote in 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861322,"accession_number":"0001493152-26-027274","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2026-06-04T20:15:33+00:00","items":["1.02"],"status":"ready","headline":"Sanara MedTech terminates Catalyst advisory agreement; shifts to soft tissue/bone fusion strategy","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On June 2, 2026, Sanara MedTech and The Catalyst Group mutually terminated their March 2023 advisory agreement.","Termination due to shift in strategy to focus on soft tissue repair and bone fusion surgical products.","No fee or penalty paid in connection with termination; certain covenants (indemnification, confidentiality) remain in effect.","Chairman Ronald T. Nixon is founder/managing partner of Catalyst and holds >5% beneficial ownership of Sanara MedTech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15483,"accession_number":"0001493152-26-022291","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2026-05-11T21:21:56+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q1 net revenue up 19% to $27.8M; GAAP EPS $0.04 vs ($0.07) loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income from continuing ops of $0.4M ($0.04 diluted EPS) vs loss of $0.6M ($0.07) YoY.","Adjusted EBITDA $4.3M (+58% YoY); gross margin improved to 93% from 92%.","Soft tissue repair revenue rose 21% to $24.9M; bone fusion revenue essentially flat at $2.9M.","Q2 2026 revenue guidance $28.5M-$29.5M (10-14% growth); full-year 2026 reaffirmed at $116M-$121M.","Sales team expanded to 43 reps; products contracted at >4,000 U.S. facilities; cash $13.6M, debt $46.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":27798534.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113892,"accession_number":"0001493152-26-012266","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q4 revenue $27.5M (+5% YoY); FY25 rev $103.1M (+19%); reaffirms FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue Q4 2025 $27.5M (+5% YoY); excluding $1.8M prior-year BIASURGE hurricane sales, growth was 13%.","Full year 2025 net revenue $103.1M (+19% YoY); net loss from continuing ops narrowed to $0.4M from $1.9M.","Adjusted EBITDA improved to $4.7M (Q4) and $17.0M (FY), vs $4.1M and $9.1M in prior year.","Reaffirmed full year 2026 financial guidance; no specific numbers provided in the release.","BIASURGE received Vizient Innovative Technology contract effective Jan 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113891,"accession_number":"0001493152-26-008547","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes investor presentation with FY2026 revenue guidance and strategy","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation to be used at TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026.","Contains summary of strategic priorities and anticipated revenue for fiscal year 2026.","Full presentation not reproduced in this 8-K; specific figures are in Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113890,"accession_number":"0001493152-26-003316","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech reports preliminary FY 2025 revenue ~$103M, guides FY 2026 revenue $116M-$121M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue expected $27.2M-$27.7M, up 3-5% YoY; excluding $1.8M BIASURGE sales in Q4'24, growth 11-13%.","FY 2025 net revenue expected $102.7M-$103.2M, ~19% YoY growth; excluding $1.8M BIASURGE, growth 21-22%.","FY 2026 guidance: net revenue $116M-$121M, growth 13-17% from 2025 midpoint.","Cash $16.6M, long-term debt $46.0M at Dec 31, 2025 (vs $15.9M cash, $30.7M debt a year earlier).","BIASURGE receives Vizient Innovative Technology contract; OsStic launch planned Q1 2027 pending FDA clearance."],"consensus_eps_estimate":0.1122,"consensus_eps_actual":-4.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":103117982.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130303,"accession_number":"0001493152-25-025152","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes investor presentation with FY2026 strategy overview","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished investor presentation for use at Piper Sandler 37th Annual Healthcare Conference on December 3, 2025.","Presentation outlines FY2026 priorities and strategy; no specific financial guidance or metrics were disclosed.","Exhibit 99.1 provided under Regulation FD; content is summary in nature and non-material."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130302,"accession_number":"0001493152-25-021715","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q3 revenue +22% to $26.3M; net income from continuing ops positive; THP discontinued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $26.3M (+22% YoY); net income from continuing ops $0.8M vs loss $0.2M; Adj. EBITDA $4.9M (+$2.3M).","Soft tissue repair revenue +24% driven by CellerateRX and BIASURGE; gross margin improved to 93% from 91%.","Operations of Tissue Health Plus (THP) ceased in Q3; $26.5M noncash impairment charge; THP classified as discontinued ops.","Net loss from discontinued ops $31.2M in Q3; overall net loss $30.4M vs $2.9M loss YoY from continuing and disc ops.","Seth Yon appointed CEO effective Sept 15, 2025; Ron Nixon remains Executive Chairman."],"consensus_eps_estimate":-0.2193,"consensus_eps_actual":-4.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":75572167.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130301,"accession_number":"0001493152-25-021615","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech discontinues Tissue Health Plus, reallocates resources to surgical business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed evaluation of strategic alternatives for THP; ceased development in late September and will discontinue operations.","THP segment will be classified as discontinued operations; wind-down expected through end of 2025.","Total cash investment in THP expected $5.5M to $6.5M in H2 2025; no material cash expenses after year-end.","Management believes surgical business has greatest potential for sustainable long-term growth and value.","Further details to be discussed on Q3 2025 earnings call scheduled for November 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146870,"accession_number":"0001493152-25-012560","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sanara MedTech appoints Seth Yon as CEO; Nixon remains Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Seth Yon promoted from President/Chief Commercial Officer to President/CEO and director, effective Sept 15, 2025.","Ron Nixon resigns as CEO but remains Executive Chairman; receives director retainer ($90K stock + $40K cash) plus $100K cash for Chairman role.","Yon employment agreement: $600K base salary, up to 100% bonus/stock awards, plus $1M one-time restricted stock grant vesting over 3 years.","Ashley Mackey designated principal accounting officer; Elizabeth Taylor remains CFO but no longer principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146869,"accession_number":"0001493152-25-011878","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q2 revenue up 28% to $25.8M; launches strategic review for Tissue Health Plus subsidiary","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $25.8M, up 28% YoY; net loss narrowed to $2.0M from $3.5M.","Adjusted EBITDA $2.7M vs $0.6M in prior-year quarter.","H1 2025: revenue $49.3M (+27%), net loss $5.5M, adjusted EBITDA $3.3M.","Sanara Surgical segment H1 adjusted EBITDA $7.4M vs $2.5M; THP segment adjusted EBITDA -$4.1M vs -$1.6M.","Company initiates process to evaluate strategic alternatives for Tissue Health Plus subsidiary."],"consensus_eps_estimate":-0.4488,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":49264930.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165322,"accession_number":"0001641172-25-012607","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Sanara MedTech posts updated investor presentation; no specific financial changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["All 8 director nominees elected at May 22 annual meeting; Weaver and Tidwell ratified as auditor.","Updated investor presentation posted to IR website on May 27, 2025.","No material financial or operational updates detailed in the furnished presentation.","Shareholder votes were routine; no contested matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165321,"accession_number":"0001641172-25-012267","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sanara MedTech CAO Michael McNeil to retire Aug 19; CFO Elizabeth Taylor to assume duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael D. McNeil to retire from Chief Accounting Officer and Chief Administrative Officer roles effective August 19, 2025.","Company is discussing a consulting arrangement with McNeil for transition and advisory services post-retirement.","CFO Elizabeth B. Taylor will become principal accounting officer following McNeil's departure.","Biographical details for Taylor available in April 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165320,"accession_number":"0001641172-25-010097","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q1 revenue up 26% to $23.4M; net loss widens to $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $23.4M (+26% YoY); net loss $3.5M vs $1.8M loss in Q1 2024.","Adjusted EBITDA improved to $0.7M from $0.3M; gross margin 92% vs 90%.","Sanara Surgical revenue drove growth; segment net loss $0.6M; Tissue Health Plus loss $2.9M.","Borrowed $12.25M under amended CRG term loan; $12.25M additional available through Dec 2025.","Appointed Elizabeth Taylor CFO; exclusive BMI license for OsStic bone void filler and ARC technology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":23434096.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165319,"accession_number":"0001641172-25-005713","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes investor presentation for Planet MicroCap Showcase; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made investor presentation available on April 22, 2025, for use at Planet MicroCap Showcase VEGAS 2025 on April 23, 2025.","No financial results, guidance changes, or material updates are included in the filing or attached exhibit.","Presentation furnished under Regulation FD; not deemed filed for SEC liability purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165318,"accession_number":"0001641172-25-002780","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Sanara MedTech acquires CarePICS for $2M cash plus $1.65M debt; draws $12.25M loan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all equity of CarePICS, a wound care telehealth platform, for $2M cash plus $1.65M debt payoff.","Potential earnout payments up to $20M: $2M per earnout period (two 12-month periods) and up to $10M in 10-year patient value earnouts.","Borrowed additional $12.25M under existing $55M term loan facility at 13.25% interest, maturity May 30, 2029.","Third draw brings total borrowed to $42.75M; up to $12.25M more available before Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182988,"accession_number":"0001641172-25-000506","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q4 net revenue up 49% to $26.3M; net loss widens to $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $26.3M (+49% YoY); full year $86.7M (+33% YoY).","Q4 net loss $1.7M vs $0.3M loss prior year; full year net loss $9.9M vs $4.4M.","Adjusted EBITDA Q4 $0.9M (vs $0.4M); full year $2.7M (vs $0.1M).","Sanara Surgical Q4 net income $0.9M; Tissue Health Plus segment loss $2.6M on platform buildout.","Exclusive license & distribution deal with BMI for OsStic bone void filler; term loan amended for additional borrowings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182987,"accession_number":"0001493152-25-003236","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sanara MedTech appoints Elizabeth Taylor as CFO, McNeil as Chief Accounting Officer & CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth Taylor appointed CFO effective Jan 15, 2025; base salary $250,000, eligible for annual restricted stock award up to 75% of salary and cash bonus up to 75% of salary.","Michael McNeil assumes roles of Chief Accounting Officer and Chief Administrative Officer; base salary increased to $234,000, bonus eligibility raised to up to 75% of salary.","Taylor joins from Imbed Biosciences where she served as CFO; holds MBA from Harvard and BA from Princeton.","Both executive employment agreements include severance provisions: one year base salary, accelerated stock vesting, and COBRA reimbursement upon qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182986,"accession_number":"0001493152-25-003234","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","8.01","7.01","9.01"],"status":"ready","headline":"Sanara MedTech acquires exclusive U.S. rights to OsStic fracture product; invests up to €8M for 12.5% of BMI","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive U.S. license/distribution for OsStic and ARC delivery tech; initial five-year term with renewal options.","Sanara invests up to €8M (€4M initial incl. debt conversion) for ~12.5% equity in BMI; remaining €4M tied to milestones.","OsStic received FDA Breakthrough Device Designation Dec 2023; U.S. market launch expected Q1 2027.","Targets >100,000 annual periarticular fracture procedures; complements existing surgical portfolio.","Company's Chief Corporate Development Officer Tyler Palmer appointed to BMI board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182985,"accession_number":"0001493152-25-003043","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech reports Q4 prelim net revenue up 45-48% YoY; FY up 32-33%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net revenue expected $25.7M-$26.2M, a 45-48% increase YoY.","Full year 2024 net revenue expected $86.0M-$86.5M, up 32-33% YoY.","BIASURGE sales benefited from ~$1.8M in temporary demand due to hurricane-related IV fluid shortages; expects normalization in Q1 2025.","Cash at Dec 31, 2024: $15.9M; debt $30.5M; $24.5M available borrowing capacity.","Appointed Keith Myers (former LHC Group CEO) to Board on Oct 4, 2024; filed 11 provisional patent applications in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":86672425.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199562,"accession_number":"0001493152-24-048602","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes investor presentation for Piper Sandler Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished for use at Piper Sandler 36th Annual Healthcare Conference on Dec 4, 2024.","No specific financial or operational details available from the provided filing text.","Presentation content not publicly disclosed in the filing; summary information only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199561,"accession_number":"0001493152-24-044829","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q3 revenue up 35% to $21.7M, net loss widens to $2.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue rose 35% YoY to $21.7M; net loss of $2.9M vs $1.1M loss in Q3 2023.","Adjusted EBITDA improved to $0.8M from $0.3M in prior-year quarter.","Appointed Keith Myers (former LHC Group CEO) to the board; invested $5.0M in ChemoMouthpiece for 6.64% stake and exclusive U.S. distribution.","Products now sold in over 1,200 facilities; contracted in 4,000+ hospitals; distributor network expanded to 300+."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":60367060.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199560,"accession_number":"0001493152-24-040275","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sanara MedTech appoints former LHC Group CEO Keith Myers to board; James Stuckert resigns as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James W. Stuckert resigned as director effective Oct 4, 2024; will remain as Director Emeritus in non-voting advisory capacity.","Keith Myers appointed to board; he co-founded LHC Group and served as chairman/CEO until LHC's merger with Optum in 2023.","Myers will serve on Corporate Development Committee; receives $90k annual board retainer and $5k committee fee under standard policy.","Stuckert's resignation was not due to any disagreement with the company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215600,"accession_number":"0001493152-24-037820","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sanara MedTech formalizes CEO Ronald Nixon employment agreement with $350K salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $350,000, one-time cash bonus of $125,000, and annual stock award potential up to 75% of salary.","Annual performance-based restricted stock award up to $625,000 based on criteria set by Compensation Committee.","Severance: one year base salary for termination without Cause or for Good Reason; two years for termination within one year of Change of Control.","Employment term of one year with automatic renewals; non-compete and non-solicit for 12 months post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215599,"accession_number":"0001493152-24-035783","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["7.01","8.01","1.01","9.01"],"status":"ready","headline":"Sanara invests $5M for 6.6% of ChemoMouthpiece, exclusive U.S. distribution via InfuSystem JV","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sanara CMP purchased 100,674.72 common units in ChemoMouthpiece for $5.0 million, a 6.64% ownership stake.","SI Technologies (50/50 JV with InfuSystem) appointed sole U.S. distributor of ChemoMouthpiece kits for 5 years.","SI Technologies has an option to purchase ChemoMouthpiece's U.S. business, including IP, expiring Jan 31, 2029.","Sanara borrowed an additional $15.5M under its CRG term loan at 13.25% per annum, maturing May 30, 2029.","Proceeds used for the ChemoMouthpiece investment; remaining funds for acquisitions and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215598,"accession_number":"0001493152-24-031301","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara Q2 revenue up 28% to record $20.2M; net loss widens to $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $20.2M, +28% YoY; eleventh consecutive record revenue quarter.","Net loss $3.5M vs $1.9M; Adjusted EBITDA $0.6M vs ($0.3M).","Secured $55M non-dilutive term loan from CRG; $15M drawn, up to $39.8M additional.","New GPO agreement adds over 1,000 contracted facilities; 300+ distributors, +70 since Jan.","Appointed Jake Waldrop as COO and Tyler Palmer as Chief Corporate Development & Strategy Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":38695461.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234957,"accession_number":"0001493152-24-024438","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes investor presentation without disclosing specific content","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an 8-K to furnish an investor presentation (Exhibit 99.1) for use in meetings and a webcast on June 20, 2024.","No financial or operational metrics from the presentation are included in the filing.","The presentation is not deemed filed and is not incorporated by reference into SEC filings.","Management intends to discuss the presentation with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234956,"accession_number":"0001493152-24-024275","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sanara MedTech shareholders approve 2024 Omnibus Long-Term Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan effective June 12, 2024, following shareholder approval at annual meeting.","Authorizes up to 1,000,000 shares of common stock for equity awards.","100% of authorized shares may be used for Incentive Stock Options.","Eligible participants: Employees, Consultants, and Outside Directors.","No further awards may be granted under the prior 2014 Restated plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234955,"accession_number":"0001493152-24-024163","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Sanara MedTech shareholders approve charter amendment, elect directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended certificate of formation to fix board size via bylaws; effective June 13, 2024.","Elected 8 directors: Nixon, DeSutter, Mack, Major, Ortwein, Salamone, Stuckert, Tanzberger; vote margins >99% of votes cast.","Approved 2024 Long-Term Incentive Plan with 5,519,016 votes for (97.3% of votes cast).","Ratified Weaver & Tidwell as independent auditor for FY2024 with 7,029,093 votes for.","Shareholder proposal on board size increase (Proposal 3) was not presented as board did not effectuate increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234954,"accession_number":"0001493152-24-021982","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sanara MedTech Inc. CEO Zachary B. Fleming Resigns, Enters Separation Agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zachary B. Fleming resigned as CEO effective May 10, 2024; separation agreement signed May 29, 2024.","Separation benefits include 12 months base salary paid in installments over 12 months.","Company to pay COBRA premiums for Fleming and dependents during the severance period.","50% of unvested restricted stock continues to vest; partial acceleration for tax withholding.","Fleming provides general release and non-disparagement covenant in exchange for benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234953,"accession_number":"0001493152-24-018808","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Sanara MedTech Q1 revenue record $18.5M; CEO Fleming resigns, Chairman Nixon takes over","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Net revenue $18.5M in Q1 2024, up 19% YoY; tenth consecutive record quarter.","Net loss $1.8M vs $1.2M loss in prior year; Adjusted EBITDA turned positive at $0.3M.","CEO Zachary Fleming resigned May 10, 2024; Board appointed Executive Chairman Ron Nixon as new CEO effective immediately.","Subsequent to quarter end, entered $55M non-dilutive term loan with CRG; received $15M at closing with option for additional $40M.","Appointed Jake Waldrop as COO and Tyler Palmer as Chief Corporate Development and Strategy Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234952,"accession_number":"0001493152-24-015133","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Sanara MedTech enters $55M non-dilutive term loan with CRG; repays $9.8M existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $55M term loan with CRG Servicing LLC; $15M drawn at close, up to $40M available in two tranches before June 30, 2025.","Interest at 13.25% p.a. (8% cash, 5.25% PIK optional); maturity March 30, 2029.","Proceeds used to retire $9.8M Cadence Bank term loan; remaining for acquisitions, working capital.","Financial covenants: maintain liquidity >$3M; minimum annual revenue of $60M (2024), $75M (2025), $85M (2026), $95M (2027), $105M (2028+).","Prepayment premiums: 10% within 1 year, 5% between 1-2 years, none after 2 years; loan secured by substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234951,"accession_number":"0001493152-24-013261","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sanara MedTech appoints Jake Waldrop COO and Tyler Palmer Chief Corporate Development Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jake Waldrop appointed COO effective April 15, 2024; base salary $315,000, eligible for annual restricted stock and cash bonus up to 75% of salary.","One-time restricted stock award of $100,000 granted within 30 days, vesting over two years.","Tyler Palmer appointed Chief Corporate Development and Strategy Officer effective April 1, 2024.","Waldrop previously VP Finance at Enovis (Foot & Ankle) and CFO at Trilliant Surgical; Palmer was SVP at AQuity Solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252796,"accession_number":"0001493152-24-011145","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech revenue up 42% to $65M in FY2023; net loss narrows to $4.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net revenue of $65.0M, up 42% from $45.8M in FY2022.","Q4 2023 record sales of $17.7M; net loss of $0.3M vs $4.2M loss in Q4 2022.","FY2023 net loss of $4.4M, improved from $8.1M loss in FY2022.","Adjusted EBITDA negative $0.3M for FY2023 vs negative $7.5M in prior year; Q4 breakeven.","Launched ALLOCYTE Plus and BIASURGE; signed exclusive license with Tufts University for peptide tech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252795,"accession_number":"0001493152-24-010985","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sanara MedTech amends bylaws; special meeting threshold raised to 25%, adds advance notice rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders now need 25% of outstanding shares to call a special meeting (was 10%).","New advance notice requirements for proposals/director nominations: 90–120 days before annual meeting anniversary.","Director removal now requires majority of all shares entitled to vote (vs. majority of shares present).","Chairman of the Board can now call special meetings; record date range extended to max 60 days.","Exclusive forum provision added for derivative claims (Texas or federal court)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252794,"accession_number":"0001493152-24-007546","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q4 revenue $17.7M, up 15.5% YoY; FY23 revenue $65.0M, up 41.8% YoY","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 net revenue $17.7M, +15.5% YoY; ninth consecutive record quarter.","FY23 net revenue $65.0M, +41.8% YoY vs $45.8M in FY22.","CellerateRX Surgical sales +31% YoY; growth driven by soft tissue repair and bone fusion products.","Cash balance $5.1M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":64989842.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270270,"accession_number":"0001493152-23-040572","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q3 revenue $16M (record), net loss narrows to $1.1M, Adj. EBITDA positive $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $16.0M, up 23% YoY; net loss $1.1M vs $1.5M loss a year ago.","Adjusted EBITDA positive $0.3M vs negative $1.6M in Q3 2022.","Acquired certain collagen assets (CellerateRX, HYCOL) in August, eliminating future royalties.","First sales of ALLOCYTE Plus and BIASURGE completed post-quarter; supply issues for ALLOCYTE resolved.","Twelve new sales reps hired in 9M 2023; products sold in over 1,000 facilities across 32 states."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":47300029.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287255,"accession_number":"0001493152-23-032997","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes investor presentation for two September conferences","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation for MicroCapClub Leadership Summit (Sept 20) and Cantor Fitzgerald Global Healthcare Conference (Sept 26).","No financial results or material disclosures included in the filing or provided in the exhibit.","Filing is a Regulation FD disclosure; presentation content not summarized in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287254,"accession_number":"0001493152-23-029069","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sanara MedTech clarifies Q2 sales per facility grew YoY but declined QoQ","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 15, 2023 earnings call, Sanara MedTech said sales per facility were growing; today's 8-K clarifies it was YoY, not QoQ.","Sequentially (Q2 2023 vs Q1 2023), sales per facility slightly declined.","Metric calculated as monthly Surgical Products sales divided by number of facilities with revenue; quarterly is average of monthly.","Surgical Products include CellerateRX, FORTIFY TRG, FORTIFY FLOWABLE, TEXAGEN, BiFORM, AMPLIFY, ALLOCYTE.","Correction filed under Regulation FD to avoid misleading investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287253,"accession_number":"0001493152-23-028632","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q2 revenue up 63% to $15.8M; acquires collagen assets to cut royalties","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 net revenues $15.8M (+63% YoY); net loss $1.9M vs net income $0.8M in prior year.","Completed post-quarter acquisition of collagen-related assets including CellerateRX Surgical and HYCOL.","Annual royalties on collagen products were $1.8M in 2022; acquisition expected to eliminate those payments.","Products sold in over 950 facilities and contracted in 3,000+ hospitals/ASCs as of June 30.","Loss before income taxes improved to $1.9M from $3.4M in Q2 2022 due to slower expense growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":31275081.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287252,"accession_number":"0001493152-23-026375","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Sanara MedTech acquires collagen assets for $15.25M; funds with $12M loan from Cadence Bank","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired IP, manufacturing rights, and four 510(k)-cleared products including CellerateRX and HYCOL.","Purchase price: $9.75M cash, $3.0M in stock (73,809 shares), $2.5M in four annual installments.","Entered $12M term loan with Cadence Bank at Term SOFR + 3%, maturing August 2028.","Sellers eligible for up to $10M earnout based on future sales of a collagen product under development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307351,"accession_number":"0001493152-23-020279","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sanara MedTech shareholders elect all eight director nominees and ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["7,365,228 shares present at June 1, 2023 meeting; all eight director nominees elected with votes for ranging from 5,512,123 to 5,564,051.","Ratification of Weaver and Tidwell, L.L.P. as auditor for FY 2023: 6,140,532 for, 0 against.","Advisory approval of executive compensation: 5,548,532 for, 24,489 against, 888 abstentions.","All three proposals received sufficient votes to pass."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307350,"accession_number":"0001493152-23-017398","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q1 revenue $15.5M, up 99% YoY; net loss narrows to $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $15.5M (99% YoY increase); net loss $1.2M vs $3.2M prior year.","Gross margin 86% vs 90% prior year due to lower margins on Scendia products.","SG&A $13.0M (up $3.6M) driven by higher sales commissions and sales force expansion.","Scendia sales flat at $3.0M; ALLOCYTE supply issues persist, expected resolution H2 2023.","Received 510(k) clearance for BIASURGE Advanced Surgical Solution; preparing launch late 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":15521917.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326383,"accession_number":"0001493152-23-008250","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech FY2022 revenue $45.8M (+90% YoY); net loss $8.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $45.8M vs $24.1M in 2021, a 90% increase; gross margin 86% vs 90%.","Net loss $8.1M vs $8.0M in 2021; SG&A expenses rose to $46.0M from $28.1M.","CellerateRX sold in over 700 facilities across 29 states; generated >$5M revenue in a single month.","Entered partnership with InfuSystem for wound care; filed 510(k) for BIASURGE and Precision Healing Imager.","Entered ATM sales agreement with Cantor Fitzgerald for stock offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326382,"accession_number":"0001493152-23-006000","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sanara MedTech enters $75M at-the-market equity offering agreement with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M of common stock may be sold from time to time through Cantor Fitzgerald & Co.","Cantor receives a 3.0% commission on gross proceeds from each sale.","Sales are at-the-market offerings under Rule 415(a)(4); no obligation to sell any shares.","Agreement may be suspended or terminated by either party upon notice.","Shares are registered under existing S-3 shelf registration statement (File No. 333-251652)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326381,"accession_number":"0001493152-23-005752","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanara MedTech Q4 revenue jumps 119% YoY to $15.3M; full-year revenue up 90% to $45.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $15.3M in Q4 2022 (up 119% from $7.0M); full-year $45.8M (up 90% from $24.1M).","Operating loss expected $2.0M-$3.5M in Q4 vs $3.4M loss prior year; full-year loss $11.0M-$12.5M vs $7.4M.","Cash and equivalents $9.0M as of December 31, 2022.","Recorded non-cash loss on dissolution of Sanara Pulsar of $1.0M in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":45842845.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344096,"accession_number":"0001493152-22-035656","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes updated investor presentation; no specific financial figures disclosed in filing.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company provided an updated investor presentation as Exhibit 99.1.","Presentation includes additional information on performance and strategy.","No revenue, earnings, or guidance figures are included in the 8-K text.","Filing is under Regulation FD; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344095,"accession_number":"0001493152-22-034594","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sanara MedTech President Shawn M. Bowman resigns; receives $60K severance and stock vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn M. Bowman resigned as President, Strategic Partnerships, effective December 2, 2022.","Receives $60,000 cash separation payment and immediate vesting of 4,519 restricted shares.","Separation includes general release of claims and non-disparagement covenant.","No replacement named; responsibilities likely absorbed by existing management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344094,"accession_number":"0001493152-22-033982","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanara MedTech furnishes investor presentation for Piper Sandler Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation used at Piper Sandler 34th Annual Healthcare Conference on Nov 30, 2022.","No specific financial or operational data from the presentation available in the filing.","Information is furnished under Item 7.01 and not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344092,"accession_number":"0001493152-22-032353","cik":714256,"company_name":"Sanara MedTech Inc.","ticker":"SMTI","form_type":"8-K/A","filed_at":"2022-11-15T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Sanara MedTech amends Q3 2022 8-K to correct CellerateRX facility count from 1,593 to 1,714","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Original filing reported CellerateRX approved in 1,593 facilities as of Sep 30, 2022.","Acquisition of Scendia Biologics added 121 facilities, bringing corrected total to 1,714.","Amendment only revises this specific number; all other disclosures remain unchanged.","No change to financial results or any other operational metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":215444903.9298546,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-15T23:59:59+00:00|344092"}